Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$6.00
0.000.00%
At close: -
$6.04
0.040.65%
After Hours: 6:14 PM EDT
Comments
Loading...
Abeona Therapeutics Analyst Ratings and Price Targets | NASDAQ:ABEO | Benzinga
Abeona Therapeutics Inc has a consensus price target of $16.75 based on the ratings of 8 analysts. The high is $20 issued by Stifel on May 16, 2025. The low is $6 issued by SVB Leerink on November 14, 2022. The 3 most-recent analyst ratings were released by Oppenheimer, Stifel, and HC Wainwright & Co. on June 2, 2025, May 16, 2025, and April 30, 2025, respectively. With an average price target of $19.67 between Oppenheimer, Stifel, and HC Wainwright & Co., there's an implied 225.64% upside for Abeona Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
Stifel
HC Wainwright & Co.
HC Wainwright & Co.
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Abeona Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/02/2025 | Buy Now | 214.61% | Oppenheimer | Andreas Argyrides71% | → $19 | Assumes | → Outperform | Get Alert |
| 05/16/2025 | Buy Now | 231.16% | Stifel | Dae Gon Ha49% | $21 → $20 | Maintains | Buy | Get Alert |
| 04/30/2025 | Buy Now | 231.16% | HC Wainwright & Co. | Raghuram Selvaraju44% | $15 → $20 | Maintains | Buy | Get Alert |
| 03/24/2025 | Buy Now | 148.37% | HC Wainwright & Co. | Mitchell Kapoor46% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2025 | Buy Now | 164.93% | Oppenheimer | Francois Brisebois39% | → $16 | Initiates | → Outperform | Get Alert |
| 02/19/2025 | Buy Now | 148.37% | HC Wainwright & Co. | Mitchell Kapoor46% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 11/25/2024 | Buy Now | 148.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | 148.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 10/29/2024 | Buy Now | 198.05% | Cantor Fitzgerald | Kristen Kluska71% | $18 → $18 | Reiterates | Overweight → Overweight | Get Alert |
| 09/20/2024 | Buy Now | 198.05% | Cantor Fitzgerald | Kristen Kluska71% | $18 → $18 | Reiterates | Overweight → Overweight | Get Alert |
| 08/14/2024 | Buy Now | 148.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 07/12/2024 | Buy Now | 148.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 07/03/2024 | Buy Now | 148.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $15 | Initiates | → Buy | Get Alert |
| 05/30/2024 | Buy Now | 247.72% | Stifel | Dae Gon Ha49% | → $21 | Initiates | → Buy | Get Alert |
| 05/16/2024 | Buy Now | 247.72% | Cantor Fitzgerald | Kristen Kluska71% | $28 → $21 | Maintains | Overweight | Get Alert |
| 04/23/2024 | Buy Now | 496.1% | Cantor Fitzgerald | Kristen Kluska71% | $36 → $36 | Reiterates | Overweight → Overweight | Get Alert |
| 08/24/2023 | Buy Now | 529.21% | Cantor Fitzgerald | Kristen Kluska71% | → $38 | Reiterates | Overweight → Overweight | Get Alert |
| 07/13/2023 | Buy Now | 529.21% | Cantor Fitzgerald | Kristen Kluska71% | → $38 | Reiterates | Overweight → Overweight | Get Alert |
| 05/24/2023 | Buy Now | 231.16% | Alliance Global Partners | James Molloy29% | → $20 | Reiterates | → Buy | Get Alert |
| 11/14/2022 | Buy Now | -0.65% | SVB Leerink | Mani Foroohar50% | $5 → $6 | Maintains | Market Perform | Get Alert |
| 11/08/2022 | Buy Now | 562.33% | Cantor Fitzgerald | Kristen Kluska71% | $22 → $40 | Maintains | Overweight | Get Alert |
| 08/11/2022 | Buy Now | -17.21% | SVB Leerink | Mani Foroohar50% | $1 → $5 | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Abeona Therapeutics (ABEO) stock?
The latest price target for Abeona Therapeutics (NASDAQ:ABEO) was reported by Oppenheimer on June 2, 2025. The analyst firm set a price target for $19.00 expecting ABEO to rise to within 12 months (a possible 214.61% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Abeona Therapeutics (ABEO)?
The latest analyst rating for Abeona Therapeutics (NASDAQ:ABEO) was provided by Oppenheimer, and Abeona Therapeutics their outperform rating.
When was the last upgrade for Abeona Therapeutics (ABEO)?
There is no last upgrade for Abeona Therapeutics
When was the last downgrade for Abeona Therapeutics (ABEO)?
There is no last downgrade for Abeona Therapeutics.
When is the next analyst rating going to be posted or updated for Abeona Therapeutics (ABEO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abeona Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abeona Therapeutics was filed on June 2, 2025 so you should expect the next rating to be made available sometime around June 2, 2026.
Is the Analyst Rating Abeona Therapeutics (ABEO) correct?
While ratings are subjective and will change, the latest Abeona Therapeutics (ABEO) rating was a with a price target of $0.00 to $19.00. The current price Abeona Therapeutics (ABEO) is trading at is $6.04, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
